Register Login

ELICIO THERAPEUTICS, INC. (ELTX)

SymbolELTX
NameELICIO THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address51 CHARLES LINDBERGH BOULEVARD, UNIONDALE, New York, 11553, United States
Telephone+1 415 655-4899
Fax—
Email—
Websitehttps://www.elicio.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001601485
Description

Elicio Therapeutics, Inc., formerly Angion Biomedica Corp., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Companys lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The Company is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The Company provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The Company conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Additional info from NASDAQ:
Elicio Therapeutics, Inc., formerly Angion Biomedica Corp., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Companys lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The Company is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The Company provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The Company conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2026-07-17 20:14

Haqq Christopher 🟢 acquired 64.6K shares (1 derivative) of Elicio Therapeutics, Inc. (ELTX) at $3.20 Transaction Date: Jul 16, 2026 | Filing ID: 000002

Read more
2026-07-17 20:14

DeMuth Peter 🟢 acquired 52.8K shares (1 derivative) of Elicio Therapeutics, Inc. (ELTX) at $3.20 Transaction Date: Jul 16, 2026 | Filing ID: 000002

Read more
2026-07-17 20:13

Shah Preetam 🟢 acquired 60.8K shares (1 derivative) of Elicio Therapeutics, Inc. (ELTX) at $3.20 Transaction Date: Jul 16, 2026 | Filing ID: 000002

Read more
2026-07-17 20:13

Director Connelly Robert 🟢 acquired 186.9K shares (1 derivative) of Elicio Therapeutics, Inc. (ELTX) at $3.20 Transaction Date: Jul 16, 2026 | Filing ID: 000002

Read more
2026-07-16 12:42

New Form SCHEDULE 13G - Elicio Therapeutics, Inc. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0002145902-26-000001 <b>Size:</b> 6 KB

Read more
2026-07-08 15:29

New Form SCHEDULE 13G/A - Elicio Therapeutics, Inc. <b>Filed:</b> 2026-07-08 <b>AccNo:</b> 0001104659-26-081751 <b>Size:</b> 9 KB

Read more
2026-07-06 20:15

A New Press Release from Elicio Therapeutics

Read more
2026-07-06 20:05

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

Read more
2026-07-02 10:20

(99% Neutral) ELICIO THERAPEUTICS, INC. (ELTX) Provides Update on agent for KRAS-driven cancers

Read more
2026-07-02 09:17

New Form 424B5 - Elicio Therapeutics, Inc. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001104659-26-080106 <b>Size:</b> 562 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07083479 Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Panc… — Pancreatic Ductal Adenocarcinoma No_Longer_Available — — ClinicalTrials.gov
NCT07399782 Botulinum Toxin in the Palatopharyngeal Muscle for the Treatment of Obstructive… Phase2 Sleep Apnea Syndrome, Obstructive Not_Yet_Recruiting 2026-04-05 2026-09-01 ClinicalTrials.gov
NCT06408363 Effectiveness of Sequential Eustachian Tube Maneuvers in Hyperbaric Oxygen Cond… Na Barotrauma;Ear Recruiting 2023-05-01 2026-12-01 ClinicalTrials.gov
NCT05726864 A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors Phase1 Pancreatic Ductal Adenocarcinoma Active_Not_Recruiting 2023-04-14 2026-11-01 ClinicalTrials.gov
NCT04853017 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcino… Phase1 Minimal Residual Disease Completed 2021-10-04 2024-09-24 ClinicalTrials.gov
NCT00832403 Gore Tex Implants in the Treatment of Atrophic Rhinitis — Atrophic Rhinitis Suspended 2006-11-01 — ClinicalTrials.gov
Total clinical trials: 6
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma NO_LONGER_AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
implants of polytetrafluoroethylene in tha nasal fossa Other Preclinical Atrophic Rhinitis SUSPENDED NCT00832403
implants of polytetrafluoroethylene in tha nasal fossa Other Preclinical Atrophic Rhinitis SUSPENDED NCT00832403
ELI-002 2P Other Phase PHASE1 Minimal Residual Disease COMPLETED NCT04853017
Maneuver group Other Approved Barotrauma;Ear RECRUITING NCT06408363
Maneuver group Other Approved Barotrauma;Ear RECRUITING NCT06408363
BOTULINUM TOXIN IN THE PALATOPHARYGEUS MUSCLE Other Phase PHASE2 Sleep Apnea Syndrome, Obstructive NOT_YET_RECRUITING NCT07399782
BOTULINUM TOXIN IN THE PALATOPHARYGEUS MUSCLE Other Phase PHASE2 Sleep Apnea Syndrome, Obstructive NOT_YET_RECRUITING NCT07399782
BOTULINUM TOXIN IN THE PALATOPHARYGEUS MUSCLE Other Phase PHASE2 Sleep Apnea Syndrome, Obstructive NOT_YET_RECRUITING NCT07399782
ELI-002 7P Other Preclinical Pancreatic Ductal Adenocarcinoma AVAILABLE NCT07083479
ELI-002 7P Other Phase PHASE1 Pancreatic Ductal Adenocarcinoma ACTIVE_NOT_RECRUITING NCT05726864
Total products: 44